公开(公告)号：US11708376B2

公开(公告)日：2023-07-25

申请号：US17049232

申请日：2019-04-22

申请人： VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

发明人： Webster L. Santos ,  Yumin Dai ,  Jose A. Santiago-Rivera ,  Jacob H. Murray

IPC分类号： A61K31/437 ,  A61K31/4985 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  A61P3/04 ,  C07F5/02 ,  A61K45/06 ,  C07D241/20

CPC分类号： C07D498/04 ,  A61K45/06 ,  A61P3/04 ,  C07D241/20 ,  C07D471/04 ,  C07D487/04 ,  C07F5/025

摘要： The disclosure provides compounds of Formula (I-A) and (I-B) and the pharmaceutically acceptable salts thereof. The variables, R, R2, R3, X1, X2, X3, Y1, Y, and Z are defined herein. Certain compounds of Formula (I-A) and (I-B) act as selective mitochondrial protonophore uncouplers that do not affect plasma membrane potential. These compounds are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH), Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, the compounds are useful for increasing lifespan. Compounds and salts of Formulae (I-A) and (I-B) are also useful for regulating glucose homeostasis or insulin action in a patient.

公开(公告)号：US20230218721A1

公开(公告)日：2023-07-13

申请号：US17916169

申请日：2021-02-26

申请人： ZHEJIANG DOER BIOLOGICS CO., LTD. ,  ZHEJIANG HEZE PHARMACEUTICAL TECHNOLOGY CO., LTD.

发明人： YANSHAN HUANG ,  YONGLU CHEN ,  WENWEN DUAN ,  XIAOFANG WEN ,  YUANYUAN LIU ,  YUAN WANG ,  SHIMEI SHENG ,  YING LIU ,  SHENG NI ,  MINGYUE ZHU ,  CHEN FANG ,  PENG SUN

IPC分类号： A61K38/22 ,  A61K47/54 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K38/22 ,  A61K47/542 ,  A61P3/04 ,  A61P3/10

摘要： An incretin analogue, a preparation method therefor, and the use thereof. The incretin analogue has a GLP-1R/GIPR/GCGR agonist activity, is a triple agonist, and can be used for lowering blood glucose, reducing fat and reducing weight.

公开(公告)号：US20230203100A1

公开(公告)日：2023-06-29

申请号：US17812993

申请日：2022-07-15

申请人： Pep2Tango Therapeutics Inc.

发明人： Cristina Martha RONDINONE ,  Soumitra S. GHOSH ,  Waleed DANHO

IPC分类号： C07K14/00 ,  A61K47/65 ,  A61K9/00 ,  A61P3/10 ,  A61P3/04 ,  A61P9/12

CPC分类号： C07K14/00 ,  A61K9/0019 ,  A61K47/65 ,  A61P3/04 ,  A61P3/10 ,  A61P9/12 ,  A61K38/00

摘要： The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control of weight loss, plasma glucose and lipid levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying and preventing neurodegeneration. Such conditions and disorders include, but are not limited to, control of food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying, obesity, diabetes and diabetes-related conditions, liver fat-associated inflammation and injury.

公开(公告)号：US20230201282A1

公开(公告)日：2023-06-29

申请号：US17996501

申请日：2021-01-29

申请人： ATOGEN CO., LTD.

发明人： Hae-Jeung LEE ,  Eun-Jung PARK ,  Ji-Hee KANG ,  Hyun-Guh BAEK ,  Gun-Seok PARK

IPC分类号： A61K35/747 ,  A61P3/04 ,  A61P1/16 ,  A61P3/06 ,  A23L33/00 ,  A23L33/135

CPC分类号： A61K35/747 ,  A61P3/04 ,  A61P1/16 ,  A61P3/06 ,  A23L33/40 ,  A23L33/135 ,  A61K2035/115

摘要： Provided is a composition for preventing and treating lipid-related metabolic diseases, the composition comprising, as an active ingredient, Lactobacillus plantarum ATG-K2 or Lactobacillus plantarum ATG-K6 isolated from fermented vegetables.

公开(公告)号：US11684626B2

公开(公告)日：2023-06-27

申请号：US17233455

申请日：2021-04-17

申请人： Board of Regents, the University of Texas System

发明人： Thomas J. Slaga ,  Jacob Junco ,  Huiyun Liang ,  Sara Reyna

IPC分类号： A61K31/56 ,  A61K31/19 ,  A61K31/05 ,  A61P3/04 ,  A61P3/10 ,  A61K9/00

CPC分类号： A61K31/56 ,  A61K9/0053 ,  A61K31/05 ,  A61K31/19 ,  A61P3/04 ,  A61P3/10 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00

摘要： Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

公开(公告)号：US20230190944A1

公开(公告)日：2023-06-22

申请号：US18050604

申请日：2022-10-28

申请人： Eli Lilly and Company

发明人： Tamer COSKUN ,  Hongchang QU

IPC分类号： A61K47/62 ,  A61K47/54 ,  A61P3/04 ,  A61P3/10 ,  A61K38/22

CPC分类号： A61K47/62 ,  A61K47/542 ,  A61K47/545 ,  A61K47/54 ,  A61P3/04 ,  A61P3/10 ,  A61K38/22

摘要： The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

公开(公告)号：US11679097B2

公开(公告)日：2023-06-20

申请号：US16637018

申请日：2018-07-13

申请人： ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD.

发明人： Dong Li ,  Quan Han ,  Liu Hu ,  Lian Xue

IPC分类号： A61K31/366 ,  A61K31/155 ,  A61K31/585 ,  A61K31/7048 ,  C07J73/00 ,  A61P3/04 ,  A61P3/10 ,  A61P3/00

CPC分类号： A61K31/366 ,  A61K31/155 ,  A61K31/585 ,  A61K31/7048 ,  A61P3/04 ,  A61P3/10

摘要： The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.

公开(公告)号：US20230181667A1

公开(公告)日：2023-06-15

申请号：US17925482

申请日：2021-05-18

申请人： BLACK IDOL

发明人： Benoît LION ,  Jérôme DE FRANCE

IPC分类号： A61K36/82 ,  A61K31/353 ,  A61K8/49 ,  A61K8/9789 ,  A61Q19/08 ,  A61P3/04 ,  A61P1/14 ,  A61P3/06 ,  A23F5/14 ,  A23L33/105 ,  B65D85/804

CPC分类号： A61K36/82 ,  A61K31/353 ,  A61K8/498 ,  A61K8/9789 ,  A61Q19/08 ,  A61P3/04 ,  A61P1/14 ,  A61P3/06 ,  A23F5/14 ,  A23L33/105 ,  B65D85/8067

摘要： The present invention relates to a liquid composition for enriching aqueous or hydro-alcoholic food, cosmetic and/or dermatological products. The invention also relates to the use of said liquid composition and to the method for producing said liquid composition.

公开(公告)号：US20230167080A1

公开(公告)日：2023-06-01

申请号：US18060027

申请日：2022-11-30

申请人： Pfizer Inc.

发明人： Leanne Marie BUZON ,  Kimberly O'Keefe CAMERON ,  Kevin Francis DEBOYACE ,  Kevin James FILIPSKI ,  David Andrew GRIFFITH ,  Bethany Lyn KORMOS ,  Shenping LIU ,  Luis Angel MARTINEZ ALSINA ,  Matthew Richard REESE ,  Rachel Jane ROTH FLACH ,  Yuan ZHANG

IPC分类号： C07D333/68 ,  A61P3/04 ,  A61P9/00

CPC分类号： C07D333/68 ,  A61P3/04 ,  A61P9/00 ,  C07B2200/13

摘要： Described herein are compounds of Formula I,




wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.

公开(公告)号：US20230159560A1

公开(公告)日：2023-05-25

申请号：US18056863

申请日：2022-11-18

申请人： AMGEN INC.

发明人： Jennifer R. ALLEN ,  Michela BELTRANI ,  Matthew P. BOURBEAU ,  Teodora P. DAMYANOVA ,  Iain LINGARD ,  Ana E. MINATTI ,  Paolo Vincetti

IPC分类号： C07D513/04 ,  A61P3/04 ,  C07D487/04 ,  C07D498/04

CPC分类号： C07D513/04 ,  A61P3/04 ,  C07D487/04 ,  C07D498/04

摘要： The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula I.




wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.